Other News Releases in Biotechnology
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries
Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category
American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
Other News Releases in Trade Show News
River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries
U.S.-China Business Summit to Host World's Largest Symposium for Americans, Chinese
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News
PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009
INCLINE VILLAGE, Nev., Oct. 27 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Oppenheimer 20th Annual Healthcare Conference in New York City on Wednesday, November 4, 2009 at 9:40 a.m. Eastern Time
To access the live and subsequently archived webcast of the conference call, go to the company's website at http://www.pdl.com and click "Investors." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. A replay will be available at www.pdl.com starting approximately three hours after completion of the webcast.
About PDL BioPharma, Inc.
PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.